{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:44:05Z","timestamp":1793375045946,"version":"4.5.0"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1121285","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:27:28Z","timestamp":1678148848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Diversity of immune checkpoints in cancer immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhangyan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume":"1248","author":"Zhang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond pd-1 and ctla-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","article-title":"Nk cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837645","article-title":"The role of immune checkpoint molecules on macrophages in cancer, infection, and autoimmune pathologies","volume":"13","author":"Brom","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","article-title":"The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer","volume":"11","author":"Bremnes","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor pd-L1 mrna expression is associated with increased tils and better outcome in breast carcinomas","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.973314","article-title":"To affinity and beyond: Harnessing the T cell receptor for cancer immunotherapy","volume":"10","author":"Thaxton","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of Cd8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"Pd-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: Pd-1\/Pd-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining Cd8+ T cells that provide the proliferative burst after pd-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature24649","article-title":"Pd-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004570117","article-title":"Klhl22 maintains pd-1 homeostasis and prevents excessive T cell suppression","volume":"117","author":"Zhou","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"Pd-1 expression on hiv-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant pd-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-Small-Cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02642-4","article-title":"Dynamics of peripheral T cell clones during pd-1 blockade in non-small cell lung cancer","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz026","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the phase iii checkmate 025 study","volume":"49","author":"Tomita","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-Neck squamous cell carcinoma (Keynote-040): A randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of ctla-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of ctla-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/Ctla-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.156.11.4154","article-title":"Regulation of ctla-4 expression during T cell activation","volume":"156","author":"Perkins","year":"1996","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.43.26762","article-title":"Covalent dimerization of Cd28\/Ctla-4 and oligomerization of Cd80\/Cd86 regulate T cell costimulatory interactions","volume":"271","author":"Greene","year":"1996","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108","article-title":"The emerging role of Ctla4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by ctla-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage Iiib\/Iv non-Small-Cell lung cancer: Results from a randomized, double-blind, multicenter phase ii study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I\/Ii study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative ctla-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-Ctla-4 and anti-Pd-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (Checkmate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-Pd-1 and anti-Ctla-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939274","article-title":"Tim-3 is expressed on activated human Cd4+ T cells and regulates Th1 and Th17 cytokines","volume":"39","author":"Hastings","year":"2009","journal-title":"Eur J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive hiv-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis c virus infection and its blockade rescues dysfunctional Cd4+ and Cd8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-113","article-title":"Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis b infection","volume":"8","author":"Wu","year":"2011","journal-title":"Virol J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and pd-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1656-8","article-title":"Role of Tim-3 in ovarian cancer","volume":"19","author":"Xu","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/Galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis b virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa701","article-title":"Immune Co-inhibitory receptors pd-1, ctla-4, Tim-3, lag-3, and tigit in medullary thyroid cancers: A Large cohort study","volume":"106","author":"Shi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/BF00241263","article-title":"Cellular expression and tissue distribution of the human lag-3-Encoded protein, an mhc class ii ligand","volume":"39","author":"Huard","year":"1994","journal-title":"Immunogenetics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393","article-title":"Lag-3, a novel lymphocyte activation gene closely related to Cd4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0800185","article-title":"Lag-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250949","article-title":"Cd4\/Major histocompatibility complex class ii interaction analyzed with Cd4- and lymphocyte activation gene-3 (Lag-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of lag-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323382","article-title":"The Cd4-related molecule, lag-3 (Cd223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of lag-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules lag-3 and pd-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of Imp321, a novel mhc class ii agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B64","first-page":"9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (Anti-Lag-3; bms-986016) in combination with nivolumab (Nivo) in pts with melanoma (Mel) previously treated with anti-Pd-1\/Pd-L1 therapy","volume-title":"J Clin Oncol","author":"Ascierto","year":"2017"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: A novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2012.12.004","article-title":"Expression of lag-3 is coincident with the impaired effector function of hbv-specific Cd8(+) T cell in hcc patients","volume":"150","author":"Li","year":"2013","journal-title":"Immunol Lett"},{"key":"B67","first-page":"39","article-title":"Upregulation of immune checkpoint molecules, pd-1 and lag-3, on Cd4+ and Cd8+ T cells after gastric cancer surgery","volume":"58","author":"Takaya","year":"2015","journal-title":"Yonago Acta Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of lag-3 defines exhaustion of intratumoral pd-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"Lag-3 protein expression in non-small cell lung cancer and its relationship with pd-1\/Pd-L1 and tumor-infiltrating lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01151-8","article-title":"Combined inhibition of pd-1\/Pd-L1, lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models","volume":"24","author":"Mimura","year":"2021","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"Tigit as an emerging immune checkpoint","volume":"200","author":"Harjunpaa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80445","article-title":"Tigit and pd-1 impair tumor antigen-specific Cd8(+) T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"Vista, a novel mouse ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"Vista regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond ctla-4 and pd-1, the generation z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5","article-title":"Vista expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ijms22010379","article-title":"Lag-3, Tim-3 and vista expression on tumor-infiltrating lymphocytes in oropharyngeal squamous cell carcinoma-potential biomarkers for targeted therapy concepts","volume":"22","author":"Wuerdemann","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwm049","article-title":"Siglec-15: An immune system siglec conserved throughout vertebrate evolution","volume":"17","author":"Angata","year":"2007","journal-title":"Glycobiology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.05.015","article-title":"Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation","volume":"409","author":"Hiruma","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bone.2015.05.029","article-title":"Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis","volume":"79","author":"Shimizu","year":"2015","journal-title":"Bone"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2925","article-title":"Siglec-15 as an emerging target for next-generation cancer immunotherapy","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3390\/cancers13174263","article-title":"Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer","volume":"13","author":"Buckle","year":"2021","journal-title":"Cancers"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150785","article-title":"Identification of Cd112r as a novel checkpoint for human T cells","volume":"213","author":"Zhu","year":"2016","journal-title":"J Exp Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: Integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural killer cell deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","article-title":"The killer immunoglobulin-like receptor gene cluster: Tuning the genome for defense","volume":"7","author":"Bashirova","year":"2006","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-1-61779-842-9_23","article-title":"Overview of the killer cell immunoglobulin-like receptor system","volume":"882","author":"Rajalingam","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.359","article-title":"Nk cell receptors","volume":"16","author":"Lanier","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360255","article-title":"Iph2101, a novel anti-inhibitory kir antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103085","article-title":"A phase ii trial of pan-Kir2d blockade with Iph2101 in smoldering multiple myeloma","volume":"99","author":"Korde","year":"2014","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of Kir2d with the monoclonal antibody Iph2101 induces contraction and hyporesponsiveness of nk cells in patients with myeloma","volume":"22","author":"Carlsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory kir mab Iph2101 for aml in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0304","article-title":"A phase I trial of the anti-kir antibody Iph2101 and lenalidomide in patients with Relapsed\/Refractory multiple myeloma","volume":"21","author":"Benson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/35869","article-title":"Hla-e binds to natural killer cell receptors Cd94\/Nkg2a, b and c","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human nk cells: Surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-Nkg2a mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and nk cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor Nkg2a overcomes tumor resistance to nk cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"Nkg2a blockade potentiates Cd8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor tigit prevents nk cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on nk cells inhibits nk-Cell-Mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317","article-title":"Contribution of nk cells to immunotherapy mediated by pd-1\/Pd-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The mechanism of anti-Pd-L1 antibody efficacy against pd-L1-Negative tumors identifies nk cells expressing pd-L1 as a cytolytic effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discovery"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2015.1052145","article-title":"The clinical significance of abnormal Tim-3 expression on nk cells from patients with gastric cancer","volume":"44","author":"Wang","year":"2015","journal-title":"Immunol Invest"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.09.017","article-title":"Increased Tim-3 expression in peripheral nk cells predicts a poorer prognosis and Tim-3 blockade improves nk cell-mediated cytotoxicity in human lung adenocarcinoma","volume":"29","author":"Xu","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of nk-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4149","article-title":"Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3\/Galectin-9 for nk cell suppression in human gastrointestinal stromal tumors","volume":"34","author":"Komita","year":"2015","journal-title":"Oncol Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"Lsectin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-2478(97)00170-3","article-title":"Lag-3 does not define a specific mode of natural killing in human","volume":"61","author":"Huard","year":"1998","journal-title":"Immunol Lett"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2014.0325","article-title":"Short communication: Low expression of activation and inhibitory molecules on nk cells and Cd4(+) T cells is associated with viral control","volume":"31","author":"Taborda","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4202","article-title":"A soluble form of lymphocyte activation gene-3 (Imp321) induces activation of a Large range of human effector cytotoxic cells","volume":"179","author":"Brignone","year":"2007","journal-title":"J Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"Lag3 (Cd223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65899","article-title":"Interactions between siglec-7\/9 receptors and ligands influence nk cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwx108","article-title":"Targeting sialic acid-siglec interactions to reverse immune suppression in cancer","volume":"28","author":"Adams","year":"2018","journal-title":"Glycobiology"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02807","article-title":"Modulation of immune tolerance Via siglec-sialic acid interactions","volume":"9","author":"Lubbers","year":"2018","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120612","article-title":"Self-associated molecular patterns mediate cancer immune evasion by engaging siglecs on T cells","volume":"128","author":"Stanczak","year":"2018","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/science.2326636","article-title":"A class I antigen, hla-G, expressed in human trophoblasts","volume":"248","author":"Kovats","year":"1990","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-2078rev","article-title":"Hla-G and immune tolerance in pregnancy","volume":"19","author":"Hunt","year":"2005","journal-title":"FASEB J"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.792","article-title":"Protection from natural killer cell-mediated lysis by hla-G expression on target cells","volume":"274","author":"Pazmany","year":"1996","journal-title":"Science"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597468","article-title":"The role of hla-G in tumor escape: Manipulating the phenotype and function of immune cells","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"Hla-G: An immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm356","article-title":"Hla-G expression in human ovarian carcinoma counteracts nk cell function","volume":"18","author":"Lin","year":"2007","journal-title":"Ann Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00917.x","article-title":"Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma","volume":"14","author":"Lin","year":"2010","journal-title":"J Cell Mol Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4772","article-title":"A functional role of hla-G expression in human gliomas: An alternative strategy of immune escape","volume":"168","author":"Wiendl","year":"2002","journal-title":"J Immunol"},{"key":"B131","article-title":"Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma","volume":"63","author":"Bukur","year":"2003","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02164","article-title":"Heterogeneity of hla-G expression in cancers: Facing the challenges","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","article-title":"Interaction between hla-G and nk cell receptor Kir2dl4 orchestrates Her2-positive breast cancer resistance to trastuzumab","volume":"6","author":"Zheng","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000413","article-title":"Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motility","volume":"185","author":"Solinas","year":"2010","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27646","article-title":"Macrophage polarity in cancer: A review","volume":"120","author":"Najafi","year":"2019","journal-title":"J Cell Biochem"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809422106","article-title":"Pd-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"Pd-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"Pd-L1 (B7-H1) and pd-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (Pd-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-Pd-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells Co-defines the efficacy of anti-Ctla-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The Cd47-signal regulatory protein alpha (Sirpa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B145","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered sirpalpha variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf","year":"2013","journal-title":"Science"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-Cd47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective blockade of the ubiquitous checkpoint receptor Cd47 is enabled by dual-targeting bispecific antibodies","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200839","article-title":"The sirpalpha-Cd47 immune checkpoint in nk cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J Exp Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/nature22076","article-title":"Slamf7 is critical for phagocytosis of haematopoietic tumour cells Via mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj5501","article-title":"Slamf3 and Slamf4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors","volume":"7","author":"Li","year":"2022","journal-title":"Sci Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2006.tb00425.x","article-title":"Stabilin-1, a homeostatic scavenger receptor with multiple functions","volume":"10","author":"Kzhyshkowska","year":"2006","journal-title":"J Cell Mol Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26457","article-title":"Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients","volume":"131","author":"Algars","year":"2012","journal-title":"Int J Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1236","article-title":"Clever-1\/Stabilin-1 controls cancer growth and metastasis","volume":"20","author":"Karikoski","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3016","article-title":"Immunotherapeutic blockade of macrophage clever-1 reactivates the Cd8(+) T-cell response against immunosuppressive tumors","volume":"25","author":"Viitala","year":"2019","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B155","article-title":"Cd24 expression is a new prognostic marker in breast cancer","volume":"9","author":"Kristiansen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27581","article-title":"Overview of Cd24 as a new molecular marker in ovarian cancer","volume":"234","author":"Tarhriz","year":"2019","journal-title":"J Cell Physiol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"Cd24 signalling through macrophage siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.29","article-title":"Alternative activation of human plasmacytoid dcs in vitro and in melanoma lesions: Involvement of lag-3","volume":"134","author":"Camisaschi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating dcs suppress nucleic acid-mediated innate immune responses through interactions between the receptor Tim-3 and the alarmin Hmgb1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"Tim-3 regulates Cd103(+) dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626-9","article-title":"Tim-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"Tim3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to pd-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Trans Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the tme to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (Icis); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell commun Signaling CCS"},{"key":"B167","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105997","article-title":"Clinical experience with ctla-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment","volume":"175","author":"Lisi","year":"2022","journal-title":"Pharmacol Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:27:33Z","timestamp":1678148853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":170,"alternative-id":["10.3389\/fimmu.2023.1121285"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1121285","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"article-number":"1121285"}}